RARE Ultragenyx Pharmaceutical Inc.

46.01
-1.3  -3%
Previous Close 47.31
Open 46.56
Price To Book 3.51
Market Cap 2327168270
Shares 50,579,619
Volume 555,078
Short Ratio
Av. Daily Volume 582,481

SEC filingsSee all SEC filings

  1. 8-K - Current report 181183525
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161035
  3. 8-K - Current report 181160031
  4. 8-K - Current report 181073600
  5. CT ORDER - Confidential treatment order 181046760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 high dose Cohort 3 to be initiated 2018 with data due mid-2019.
DTX301
Ornithine Transcarbamylase (OTC) Deficiency
Approved under priority review November 15, 2017.
MEPSEVII (vestronidase alfa)
Mucopolysaccharidosis 7 (MPS 7)
Phase 3 data released October 26, 2018 - endpoints not met.
UX007 (triheptanoin)
Glut1 DS patients with the movement disorder phenotype
Phase 3 data released August 22, 2017 - endpoints not met.
Aceneuramic acid extended release (Ace-ER)
GNE Myopathy
Approval announced April 17, 2018.
Crysvita (Burosumab)
X-Linked Hypophosphatemia (XLH)
Data released September 2018.
KRN23 Burosumab
Tumor-induced osteomalacia (TIO)
NDA to be filed mid-2019.
UX007 (triheptanoin)
Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Phase 3 data in pediatric patients released May 17, 2018 - primary endpoint met.
KRN23 Burosumab
X-Linked Hypophosphatemia (XLH)
Phase 1/2 low dose cohort data due YE 2018.
DTX401
GSD1

Latest News

  1. See what the IHS Markit Score report has to say about Ultragenyx Pharmaceutical Inc.
  2. Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Ultragenyx Pharmaceutical
  3. Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children
  4. Ultragenyx (RARE) Down 7.2% Since Last Earnings Report: Can It Rebound?
  5. Edited Transcript of RARE earnings conference call or presentation 5-Nov-18 10:00pm GMT
  6. Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019
  7. Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments
  8. Ultragenyx (RARE) Posts Narrower-Than-Expected Loss in Q3
  9. Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
  10. Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
  11. Ultragenyx: 3Q Earnings Snapshot
  12. Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update
  13. Drug Stocks to Post Earnings on Nov 5: MYL, NBIX, RARE, TARO
  14. Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal
  15. Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update
  16. Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders

SEC Filings

  1. 8-K - Current report 181183525
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181161035
  3. 8-K - Current report 181160031
  4. 8-K - Current report 181073600
  5. CT ORDER - Confidential treatment order 181046760
  6. 8-K - Current report 181044439
  7. 8-K - Current report 181032951
  8. 8-K - Current report 18990125
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 18989872
  10. 8-K - Current report 18988393